Allergan Fortifies Defenses In Response To Valeant’s Hostile Bid
This article was originally published in The Gray Sheet
Allergan’s board adopted a so-called poison pill stockholder rights plan to hold off Valeant’s hostile takeover effort while it reviews the unsolicited offer.
You may also be interested in...
The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.